Kaleido Biosciences, Inc. KLDO
0.00 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.00001 52-week range 0.20005
- YTD
- 0.00%
- 1 year
- 0.00%
Analyst view
Consensus: hold
Hold
Price target (mean) 22.00
Ratings (-1m) 6 4 buy · 0 hold · 2 sell
- Strong buy1
- Buy3
- Hold0
- Sell2
- Strong sell0
Recommendation trend
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.51 | -0.51 – -0.51 | -0.58 | +12.1% | 0 | 0.0% | 1 |
| Next quarter | -0.25 | -0.25 – -0.25 | -0.56 | +55.4% | 0 | 0.0% | 1 |
| Current year | -1.16 | -1.16 – -1.16 | -2.16 | +46.3% | 0 | 0.0% | 1 |
| Next year | -0.85 | -0.85 – -0.85 | -1.16 | +26.7% | 30.00M | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 4, 2022 | Chardan Capital | Downgrade | Buy | Neutral |
| Jan 31, 2022 | Chardan Capital | Maintained | — | Buy |
| Nov 12, 2021 | Chardan Capital | Maintained | — | Buy |
| Nov 3, 2021 | JMP Securities | Maintained | — | Market Outperform |
| Oct 19, 2021 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Mar 8, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Feb 9, 2021 | Piper Sandler | Initiated | — | Overweight |
| Jan 19, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Dec 23, 2020 | JMP Securities | Initiated | — | Outperform |
| Aug 10, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| May 21, 2020 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Apr 23, 2019 | Chardan Capital | Initiated | — | Buy |
| Mar 25, 2019 | JP Morgan | Initiated | — | Neutral |
| Mar 25, 2019 | Goldman Sachs | Initiated | — | Buy |
| Mar 25, 2019 | Canaccord Genuity | Initiated | — | Buy |
| Mar 25, 2019 | Morgan Stanley | Initiated | — | Overweight |